Recent studies suggest that CD169+ macrophages in tumor regional lymph nodes are positively associated with favorable prognosis in patients with colorectal cancer, bladder cancer, endometrial carcinoma, or malignant melanoma (65–68). Here, SIGLEC1 is linked to colorectal cancer.